Answers are grounded in this paper and cite their sources.
SUMMARY Recent developments in transfusion practices are prompting re‐evaluation of platelet therapy. For example, the use of single‐donor apheresis products has increased substantially, from 365,000 units in 1989 to 607,000 in 1992 and to 714,000 in 1994, as shown in Table 1 1 ; in some regions, apheresis platelets account for 70% of transfusions 2 .The use of these components has been driven in part by the need for adequate platelet inventory in order to support cardiac surgery and hematopoietic stem cell transplantation programs, but also in part by commercial interests, in which promotion of the use of leucodepleted platelet products targets surgeons directly 3 . However, emerging issues related to the handling of the apheresis donor 4, 5 , the higher costs of apheresis platelets compared to pooled platelet concentrates 6 8 , and the results of the TRAP (Transfusion‐Related Alloimmunization to Platelets 9,10 ) study have caused renewed debate regarding the role of apheresis platelets compared to platelet concentrates. Furthermore, recent studies have suggested alternative strategies in platelet therapy. These strategies include the platelet threshold for prophylactic platelet transfusion, platelet transfusion dose, and the emerging role of thrombopoietin therapy; these developments will be reviewed in this article.
No takes yet. Share an insight, caveat, or question.
Lawrence T. Goodnough (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: